The Artificial Intelligence (AI) in Clinical Trials Market is rapidly transforming the landscape of drug development by enhancing trial efficiency, accuracy, and patient outcomes. AI technologies such as machine learning (ML), natural language processing (NLP), and predictive analytics are increasingly being integrated into various stages of clinical research—from patient recruitment and trial design to data monitoring and predictive modeling. By enabling real-time analysis of large, complex datasets, AI helps reduce trial timelines, minimize costs, and improve the overall success rate of drug candidates.
According to Fortune Business Insights, the AI in clinical trials market share was valued at USD 2.76 billion in 2024 and is projected to grow from USD 3.80 billion in 2025 to USD 54.81 billion by 2032, exhibiting an exceptional CAGR of 46.43% during the forecast period. North America dominated the market, accounting for a 52.89% share in 2024.
The AI in Clinical Trials Market encompasses a wide range of technologies and applications that support every phase of clinical development. The report covers AI software platforms, machine learning tools, predictive analytics, and data-driven decision-making systems used by pharmaceutical firms, CROs, and healthcare providers. It includes an in-depth analysis of emerging technologies, partnerships, funding trends, and market segmentation by deployment model, end-user, and region.
Prominent companies operating in the AI in Clinical Trials Market include: